课题基金 / 基金详情

A PHASE I STUDY OF A COMBINATION OF YTTRIUM-90 LABELED HUMANIZED ANTI-CEA M5A

A PHASE I STUDY OF A COMBINATION OF YTTRIUM-90 LABELED HUMANIZED ANTI-CEA M5A
YTTRIUM-90 标记的人源化抗 CEA M5A 组合的 I 期研究
批准号：
7716670
负责人：
JEFFREY Y WONG
金额：
$2.28万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
项目状态：
已结题
起止时间：
2008-04-20 至 2008-11-30
来源：
https://reporter.nih.gov/project-details/7716670
关键词：
90YAnti-CEA AntibodyAntibodiesComputer Retrieval of Information on Scientific Projects DatabaseFundingGrantInstitutionLabelMaximum Tolerated DosePhasePhase I Clinical TrialsRadioimmunoconjugateResearchResearch PersonnelResourcesSourceTherapeutic AgentsUnited States National Institutes of Healthchemotherapygemcitabine

项目摘要

项目成果

JEFFREY Y WONG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A Phase I trial will evaluate the therapeutic agent Y-90-M5A-humanized anti-CEA antibody in combination with Gemcitabine chemotherapy. It will define the maximum tolerated dose of the radiolabeled antibody in combination with Gemcitabine. In addition, immunogenecity of the antibody will be assessed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
A PHASE I TRIAL OF RADIOIMMUNOTHERAPY (Y-90 CT8466), GEMCITABINE AND HEPATIC
A PHASE I TRIAL OF RADIOIMMUNOTHERAPY (Y-90 CT8466), GEMCITABINE AND HEPATIC
海外基金